Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

February 6, 2018

Study Completion Date

December 11, 2018

Conditions
Acute Leukemia
Interventions
OTHER

Non Interventional study

The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.

Trial Locations (1)

44093

Nantes University Hospital, Nantes

All Listed Sponsors
collaborator

Centre de Recherche en cancérologie Nantes-Angers - CRCNA

UNKNOWN

lead

Nantes University Hospital

OTHER

NCT02693899 - Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia | Biotech Hunter | Biotech Hunter